AMERI_1170x120_11-6-20

AAM

AAM issues statement on the Trump Administration’s “Most Favored Nation” model

AAM issues statement on the Trump Administration’s “Most Favored Nation” model

WASHINGTON — AAM and its Biosimilars Council commend the Administration for today’s effort to remove perverse rebate incentives now blocking competition in the U.S. prescription drug marketplace, but further action is necessary to modernize the Medicare Part D program and ensure that patients and taxpayers realize the full value of lower cost generic and biosimilar

Dan Leonard named CEO of AAM

Dan Leonard named CEO of AAM

WASHINGTON — Dan Leonard on Tuesday was named president and chief executive officer of the Association for Accessible Medicines. He will join AAM in September. He most recently served as president and CEO of the National Pharmaceutical Council (NPC), and succeeds Chester “Chip” Davis, Jr. who left AAM in February to head the Healthcare Distribution

Generic drugs see low abandonment rate

Generic drugs see low abandonment rate

WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics

AAM: REMS abuse trips up new generics

AAM: REMS abuse trips up new generics

The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly